CROs/Service Providers

MedSource acquires Datatrial data services division

Wednesday, June 14, 2017

Houston-based MedSource expanded its clinical development repertoire, acquiring the data services division of biometrics and technology company Datatrial in early 2017. The deal both strengthens MedSource’s position as a full-service CRO and paves the way for a greater presence within the European market, accelerating MedSource’s growth trajectory as a result.

[Read More]

Chiltern launches Medidata Rave Value Accelerators

Monday, June 12, 2017

Chiltern, a global CRO, has announced the release of its new Medidata Rave Value Accelerators, a system of tools designed to capture, manage and report clinical research data. The tools streamline the clinical trial process and help trial sponsors cut the time, cost and effort of bringing a new device to market.

[Read More]

SynteractHCR, The GOG Foundation partner

Wednesday, June 7, 2017

SynteractHCR, a full-service, international CRO, and The GOG Foundation, a nonprofit focused on gynecologic oncology research, have signed a Teaming Agreement to work together on gynecologic oncology clinical studies. The relationship will offer a streamlined process for drug development companies to improve the timeliness of determining clinical research studies as well as facilitate high quality, rapid trial execution. The relationship is reciprocal and has a three-year term.

[Read More]

genae invests in Meditrix

Tuesday, June 6, 2017

genae, a global CRO and service provider for the medical industries, announced the closing of an investment in Meditrix. The clinical research group further obtained a call option to acquire all remaining shares of Meditrix.

[Read More]

Eisai, Charles River Laboratories extend drug discovery partnership

Monday, June 5, 2017

Eisai, a global research and development-based pharmaceutical company, and Charles River Laboratories International, an early-stage CRO, announced an agreement to extend their two-year collaboration in integrated drug discovery for another year. The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai’s 14.5 acre, state-of-the-art European Knowledge Centre.

[Read More]